We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The US Food and Drug Administration (FDA) has approved female-focused pharmaceutical company TherapeuticsMD’s TX-001HR (Bijuva) for the treatment of vasomotor symptoms, such as hot flushes, due to menopause.
In a trial carried out at Imperial College London, researchers showed that women who suffered seven or more hot flushes a day could reduce the number by as much as 73%, as well as reducing their severity and impact.